Pooled phase 2/3 trials show 78% complete response with UGN-102 in recurrent low-grade NMIBC
Retrospective · Urol Oncol · 2026-11-17. Number 3 in the UrologyWatch Top 5 for November 17, 2026.
A pooled exploratory analysis of four phase 2/3 trials found 78.3% complete response at 3 months with UGN-102 in recurrent low-grade intermediate-risk NMIBC, with 79.7% remaining event-free at 12 months after response in the ATLAS/ENVISION subset. Within the ATLAS trial, UGN-102 showed higher 3-month CR (73.7% vs 51.5%) and higher 12-month event-free probability after CR (68.8% vs 44.2%) than TURBT.
Why it matters: Pooled phase 2/3 data add longer-term efficacy and safety evidence for UGN-102, an FDA-approved nonsurgical option for recurrent low-grade NMIBC.
Limitation: Exploratory pooled analysis across trials with different designs; not a single randomized comparison.
Source: Urol Oncol · PubMed 43039768 · DOI 10.1016/j.urolonc.2026.10.004
Loading today's edition…